Eric Thomas Schmidt - 17 Dec 2021 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Reporting relationship: Director
Issuer ticker: RLMD
Reported as of: 17 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 May 2022, 18:41:00 UTC
Prior SEC filing: 24 Jun 2021
Next SEC filing: 17 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Eric Schmidt

Filing notes and source

Key filing fact

Eric Thomas Schmidt filed Form 4 for RELMADA THERAPEUTICS, INC. (RLMD) on 26 May 2022.

Key facts

This page summarizes Eric Thomas Schmidt's Form 4 filing for RELMADA THERAPEUTICS, INC. (RLMD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 May 2022, 18:41.

Change

Previous filing in this sequence was filed on 24 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RLMD transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +91,235
Change %: +155%
Price: $0.000000
Shares after: 150,000
Date: 25 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 91,235
Exercise price: $19.03
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.

Footnote F2

The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022.